<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092884</url>
  </required_header>
  <id_info>
    <org_study_id>092009-036</org_study_id>
    <nct_id>NCT01092884</nct_id>
  </id_info>
  <brief_title>Polypodium Leucotomos Extract for the Treatment of Melasma</brief_title>
  <official_title>Polypodium Leucotomos Extract as an Adjunct to Sunscreen for the Treatment of Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Industrial Farmaceutica Cantabria, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <brief_summary>
    <textblock>
      We will assess whether oral supplementation with Polypodium leucotomos, a commercially
      marketed fern extract, improves facial melasma in Hispanic women with moderate to severe
      melasma. Subjects will be randomized to either Group 1, which will receive oral Polypodium
      leucotomos extract plus topical sunscreen, or Group 2, which will receive oral placebo plus
      topical sunscreen. The study will last 12 weeks, and we hypothesize that the Polypodium
      leucotomos group will have more improvement in their melasma compared to the placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mexameter score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using rapid, non-invasive, narrow-band reflectance spectrophotometry (Mexameter), we will assess change in intensity of pigment in affected skin versus unaffected skin at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MASI Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will use the standardized Melasma Area and Severity Index (MASI) score, assessed by blinded physician investigator, to assess change in severity of melasma at 12 weeks compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melasma-Related Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
    <description>We will use a validated questionnaire tool to assess change in melasma-related quality of life at 12 weeks compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Polypodium leucotomos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive oral supplementation with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polypodium leucotomos extract</intervention_name>
    <description>240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily</description>
    <arm_group_label>Polypodium leucotomos</arm_group_label>
    <other_name>Heliocare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This placebo capsule will be taken orally three times daily</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hispanic female with moderate to severe facial melasma

        Exclusion Criteria:

          -  Currently pregnant or breastfeeding

          -  Recent use of hydroquinone, topical retinoids, topical steroids, or mechanically
             abrading procedures (such as laser therapy or dermabrasion) to the face

          -  Frequent use of tanning parlors
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melasma</keyword>
  <keyword>sunscreen</keyword>
  <keyword>polypodium leucotomos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

